iTeos Therapeutics, Inc.

NasdaqGM ITOS

iTeos Therapeutics, Inc. Receivables for the quarter ending September 30, 2024: USD 42.80 M

iTeos Therapeutics, Inc. Receivables is USD 42.80 M for the quarter ending September 30, 2024, a 578.12% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

iTeos Therapeutics, Inc. Receivables for the quarter ending September 30, 2023 was USD 6.31 M, a 38.33% change year over year.
iTeos Therapeutics, Inc. Receivables for the quarter ending September 30, 2022 was USD 4.56 M, a -15.97% change year over year.
iTeos Therapeutics, Inc. Receivables for the quarter ending September 30, 2021 was USD 5.43 M.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqGM: ITOS

iTeos Therapeutics, Inc.

CEO	Dr. Michel Detheux Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	157
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years